Latest Conference Articles

October 7th 2017, 11:46pm

NCCN Hematologic Malignancies Congress

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

October 6th 2017, 10:01pm

Global Congress on Bladder Cancer

Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.

October 6th 2017, 10:01pm

Global Congress on Bladder Cancer

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

October 6th 2017, 10:01pm

Global Congress on Bladder Cancer

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

October 6th 2017, 9:47pm

Global Congress on Bladder Cancer

Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence

October 6th 2017, 9:38pm

Global Congress on Bladder Cancer

A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.

October 6th 2017, 1:37am

Global Congress on Bladder Cancer

Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.

October 6th 2017, 12:21am

Global Congress on Bladder Cancer

Badrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.

October 6th 2017, 12:19am

Global Congress on Bladder Cancer

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

October 5th 2017, 11:40pm

Global Congress on Bladder Cancer

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

October 5th 2017, 10:26pm

Global Congress on Bladder Cancer

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

September 18th 2017, 3:00pm

International Liver Cancer Association Annual Conference

Direct acting antivirals are a novel and completely oral hepatitis C therapy that is associated with a high response rate in hepatocellular carcinoma (HCC).

September 17th 2017, 11:56pm

International Liver Cancer Association Annual Conference

BLU-554 induced an overall response rate of 16% in patients with FGF19-positive hepatocellular carcinoma.

September 17th 2017, 11:51pm

Lynn Sage Breast Cancer Symposium

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses endocrine therapy for patients with breast cancer.

September 17th 2017, 11:49pm

Lynn Sage Breast Cancer Symposium

Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, discusses challenges facing geriatric patients with breast cancer.

September 17th 2017, 11:46pm

Lynn Sage Breast Cancer Symposium

Ongoing studies are hoping to find a biomarker to guide which premenopausal women with ER-positive breast cancer need extended adjuvant therapy and which need ovarian function suppression.

September 17th 2017, 10:56pm

Lynn Sage Breast Cancer Symposium

Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.

September 17th 2017, 10:33pm

Lynn Sage Breast Cancer Symposium

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

September 17th 2017, 10:22pm

International Liver Cancer Association Annual Conference

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the purpose of the CheckMate-040 trial, which explored nivolumab (Opdivo) in patients with hepatocellular carcinoma. (HCC).

September 17th 2017, 10:21pm

International Liver Cancer Association Annual Conference

Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).